Publications by authors named "Mohammed K Mohammed"

Article Synopsis
  • The study investigates the effectiveness of robot-assisted extended total mesorectal excision (R-eTME) versus laparoscopic-assisted extended total mesorectal excision (L-eTME) in treating patients with lateral lymph node metastasis, following concurrent neoadjuvant chemo-radiation and total mesorectal excision (TME).
  • Results indicate that R-eTME has advantages over L-eTME in terms of lower overall recurrence rates and fewer urinary complications, while L-eTME was associated with longer hospital stays and slightly shorter operative times.
  • The conclusion emphasizes that, although both techniques share similar long-term outcomes, R-eTME appears to be the better option for reducing
View Article and Find Full Text PDF

Because of the insidious character and variations in presenting symptoms, Charcot-Marie-Tooth (CMT) disease is challenging to diagnose in children. Diagnosis is based on clinical and nerve conduction studies, as well as genetic examination. Therefore, competent nerve imaging techniques and non-invasive alternatives to nerve conduction studies are a necessity, especially in children.

View Article and Find Full Text PDF

Background: Delirium is common in the ICU, with incidence rates reported to be upwards of 70%. Due to the significant morbidity and mortality associated with delirium, it is hypothesised that a delirium-free sedative agent will improve outcomes in older adults admitted to the ICU.

Objectives: To assess if dexmedetomidine sedation is associated with a reduction in ICU delirium among older adults, and to evaluate its risks and benefits compared with propofol sedation.

View Article and Find Full Text PDF

Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to generic companies to mass produce the DAAs sofosbuvir and daclatasvir at low cost. However, generic manufacturers need to demonstrate bioequivalent pharmacokinetics for their DAAs, compared to the originator versions, to fulfil World Health Organization standards for prequalification.

View Article and Find Full Text PDF